Eli Lilly to leverage Sangamo capsid technology for CNS disease therapies

Sangamo Therapeutics ( NASDAQ: SGMO ) has agreed to license its neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, to Eli Lilly ( NYSE: LLY ) for one target to deliver genomic medicine to treat central nervous system diseases. Sangamo is up ~28% in after-hours trading Thursday. The.